journal article·2021-06-09Open access

Bio-Inspired Amphoteric Polymer for Triggered-Release Drug Delivery on Breast Cancer Cells Based on Metal Coordination

Pin-Chun Chen, James J. Lai, Chun-Jen Huang

ACS Applied Materials & Interfaces· Volume 13· Issue 22

Abstract

Nanoscale coordination polymers are promising vehicles for anticancer drug delivery because their surface composition and particle size can be tuned to exploit the enhanced permeability and retention effect, and their reversible interaction with metal cations enables triggered drug release at the tumor site. Here, we develop a novel nanoscale coordination polymer using the diblock copolymer poly(2-methacryloyloxyethyl phosphorylcholine)-block-poly(serinyl acrylate) (PMPC-b-PserA) and demonstrate its use for encapsulation of a hydrophobic drug and triggered drug release to induce breast cancer cell apoptosis in vitro. The zwitterionic PMPC block was inspired by the antifouling structure of cell membranes, and the PserA block was inspired by the amphoteric amino acids of proteins. The polymer was synthesized by reversible addition–fragmentation chain transfer polymerization, and a mixture of the polymer and FeCl3 self-assembled into nanoparticles via complexation of Fe3+ with PserA, with the hydrophilic PMPC block at the particle surface. At a molar ratio of Fe3+ to serA of 3:1, the hydrodynamic diameter of the particles was 22.2 nm. Curcumin, a natural water-insoluble polyphenol used to enhance the effects of chemotherapeutics, was encapsulated in the particles as an oil-in-water emulsion, with an encapsulation efficiency of 99.6% and a particle loading capacity of 32%. Triggered release of curcumin was achieved by adding deferoxamine, an FDA-approved Fe3+ chelating agent; curcumin release efficiency increased at higher deferoxamine concentrations and lower pH. Triggered release of curcumin induced apoptosis in human triple-negative breast cancer cells; cell viability decreased to 34.3% after 24 h of treatment with the curcumin-loaded nanoparticles and deferoxamine, versus >80% viability without deferoxamine to trigger drug release. The biocompatibility, tunable composition and size, high hydrophobic drug loading, and triggered-release capability of this nanoscale coordination polymer make it well-suited for use in anticancer drug delivery.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Dendrimers and Hyperbranched Polymers · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical & Materials Engineering, National Central University, Jhong-Li, Taoyuan 320, Taiwan

Department of Biomedical Sciences and Engineering, National Central University, Jhong-Li, Taoyuan 320, Taiwan

Department of Bioengineering, University of Washington, Seattle, Washington 98195, United States

R&D Center for Membrane Technology, Chung Yuan Christian University, 200 Chung Pei Road, Chung-Li City 32023, Taiwan

NCU-Covestro Research Center, National Central University, Jhong-Li, Taoyuan 320, Taiwan

Funding

Ministry of Science and Technology of the People's Republic of China · Kaohsiung Veterans General Hospital · National Institutes of Health · University System of Taiwan Joint Research Program

References (60)

Show source-provided references
1. 10.1021/ja073231f10.1021/ja073231f ↗
2. 10.1016/j.biomaterials.2013.05.06910.1016/j.biomaterials.2013.05.069 ↗
3. 10.7150/thno.1485810.7150/thno.14858 ↗
4. 10.1038/s41392-017-0004-310.1038/s41392-017-0004-3 ↗
5. 10.2147/dddt.s21948910.2147/dddt.s219489 ↗
6. Jain, K. K. Drug Delivery Systems—An Overview; Methods in Molecular Biology; Springer, 2008; Vol. 437, pp 1–50.10.1007/978-1-59745-210-6_1 ↗
7. 10.1016/s0939-6411(99)00039-910.1016/s0939-6411(99)00039-9 ↗
8. 10.1016/j.jconrel.2015.06.01910.1016/j.jconrel.2015.06.019 ↗
9. 10.1186/1556-276x-8-10210.1186/1556-276x-8-102 ↗
10. 10.3109/02652048.2011.64633010.3109/02652048.2011.646330 ↗
11. 10.1016/j.progpolymsci.2013.07.00510.1016/j.progpolymsci.2013.07.005 ↗
12. 10.1016/j.polymer.2008.01.02710.1016/j.polymer.2008.01.027 ↗
13. 10.1016/j.addr.2006.09.00410.1016/j.addr.2006.09.004 ↗
14. 10.1016/j.jare.2018.06.00510.1016/j.jare.2018.06.005 ↗
15. 10.1007/s11671-009-9427-210.1007/s11671-009-9427-2 ↗
16. 10.1016/j.jconrel.2014.06.04210.1016/j.jconrel.2014.06.042 ↗
17. 10.1016/j.canlet.2013.02.03210.1016/j.canlet.2013.02.032 ↗
18. 10.1002/adem.20108008810.1002/adem.201080088 ↗
19. 10.1038/srep4668810.1038/srep46688 ↗
20. 10.1021/ja803383k10.1021/ja803383k ↗
21. 10.1016/bs.adioch.2020.03.00110.1016/bs.adioch.2020.03.001 ↗
22. 10.1038/ncomms518210.1038/ncomms5182 ↗
23. 10.1002/anie.20080425510.1002/anie.200804255 ↗
24. 10.1002/chem.20130266210.1002/chem.201302662 ↗
25. 10.1016/s0168-3659(99)00248-510.1016/s0168-3659(99)00248-5 ↗
26. 10.1016/j.addr.2010.10.00810.1016/j.addr.2010.10.008 ↗
27. 10.1021/acsami.7b0753510.1021/acsami.7b07535 ↗
28. 10.1021/cr100449n10.1021/cr100449n ↗
29. 10.1007/s10965-019-1976-110.1007/s10965-019-1976-1 ↗
30. 10.1002/app.4176610.1002/app.41766 ↗
31. 10.1002/jbm.a.3663510.1002/jbm.a.36635 ↗
32. 10.1021/ma980495110.1021/ma9804951 ↗
33. 10.1177/1934578x1984817910.1177/1934578x19848179 ↗
34. 10.1016/j.phymed.2009.04.00810.1016/j.phymed.2009.04.008 ↗
35. 10.1016/s0014-5793(02)02292-510.1016/s0014-5793(02)02292-5 ↗
36. 10.3892/ijmm_0000015310.3892/ijmm_00000153 ↗
37. 10.3390/molecules2414252710.3390/molecules24142527 ↗
38. 10.2174/092986703345759310.2174/0929867033457593 ↗
39. 10.1016/j.epsl.2008.02.02210.1016/j.epsl.2008.02.022 ↗
40. 10.1021/ma980615510.1021/ma9806155 ↗
41. 10.1016/j.jcis.2018.10.00110.1016/j.jcis.2018.10.001 ↗
42. 10.1016/j.ijpharm.2016.01.02010.1016/j.ijpharm.2016.01.020 ↗
43. 10.1186/s40591-015-0039-110.1186/s40591-015-0039-1 ↗
44. 10.1155/2011/37030810.1155/2011/370308 ↗
45. Ashmead H. D. · 1991 · 445 · 30610.1021/bk-1991-0445.ch024 ↗
46. 10.1039/c5ra08843g10.1039/c5ra08843g ↗
47. 10.1021/la503553y10.1021/la503553y ↗
48. 10.15866/ireche.v5i2.690910.15866/ireche.v5i2.6909 ↗
49. 10.1002/marc.20130048110.1002/marc.201300481 ↗
50. 10.1021/ja200328s10.1021/ja200328s ↗
51. 10.1039/c6sc00006a10.1039/c6sc00006a ↗
52. 10.1016/j.arabjc.2014.08.01710.1016/j.arabjc.2014.08.017 ↗
53. 10.1021/acsanm.0c0041010.1021/acsanm.0c00410 ↗
54. 10.1016/j.ejpb.2016.10.01410.1016/j.ejpb.2016.10.014 ↗
55. 10.1016/s0165-6147(02)01989-210.1016/s0165-6147(02)01989-2 ↗
56. 10.1016/j.jcis.2010.10.02410.1016/j.jcis.2010.10.024 ↗
57. 10.1208/s12248-012-9432-810.1208/s12248-012-9432-8 ↗
58. 10.1002/bip.36026001210.1002/bip.360260012 ↗
59. 10.1002/bip.36032081510.1002/bip.360320815 ↗
60. International Organization for Standardization. Biological Evaluation of Medical Devices—Part 5: Tests for in Vitro Cytotoxicity, 2009 ISO standard no. 10993-5:2009 Retrieved from https://www.iso.org/standard/36406.html.